A Nursing Perspective on PARP Inhibitors in Prostate Cancer
Jun 30, 2022•12 min•Ep. 61
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode, Brenda Martone, MSN, ANP-BC, AOCNP describes recent evidence on PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) and discusses best practices for incorporating PARP inhibitors into clinical practice. Topics include:
- An overview of the PROpel study of olaparib and the TRITON study of rucaparib
- FDA-approved indications for olaparib and rucaparib
- Genetic and molecular testing for BRCA1/2 and other HRR mutations
- Managing adverse events associated with olaparib and rucaparib
- Monitoring for and managing anemia
- Gastrointestinal side effects
- Fatigue
- A look at the future of PARP inhibitors in mCRPC with combination approaches of AR-directed therapy and PARP inhibition
Presenter:
Brenda Martone, MSN, ANP-BC, AOCNP
Nurse Practitioner
Division of Genitourinary Oncology
Northwestern Medicine
Chicago, Illinois
Link to full program:
PCE.is/Onc22
For the best experience, listen in Metacast app for iOS or Android